 |
Shanghai, China; Cambridge, Massachusetts, USA; and Rotterdam, NetherlandsJune 11, 2026 /PRNewswire/ — Harbour BioMed (stock code: 02142.HK), a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies in immunology, oncology, and other therapeutic areas, today announced the appointment of Dr. Luisa Salter-Cid as a scientific advisor.
Dr. Luisa Salter-Cid brings over 20 years of distinguished leadership experience in the biotechnology and pharmaceutical industries, having held senior management positions at Flagship Pioneering, Bristol Myers Squibb (BMS), and Gossamer Bio, among others. She possesses deep expertise in immunology and immuno-oncology, with a proven track record of successfully translating scientific discoveries into clinical-stage drug candidates.
Dr. Salter-Cid currently serves as a Venture Partner at Osage University Partners (OUP), a top-tier venture capital firm focused on investing in the commercialization of university research. Previously, she was Chief Scientific Officer at Pioneering Medicines, a Flagship Pioneering initiative, where she led the development of breakthrough therapeutics leveraging the diverse scientific platforms within the Flagship ecosystem. Prior to joining Flagship, she served as Chief Scientific Officer at Gossamer Bio, playing a key role in building the company’s immunology and immuno-oncology portfolio.
Dr. Salter-Cid’s tenure at Bristol Myers Squibb further underscores her exceptional capabilities. Over a 13-year period, she served as Vice President and Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery. In this role, she led her team to successfully advance more than 20 compounds into clinical development. Throughout her career, Dr. Salter-Cid has published over 90 papers and holds multiple patents.
Dr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed, said: “We are delighted to welcome Dr. Salter-Cid to our Scientific Advisory Board. Her deep expertise in immunology and immuno-oncology, along with her outstanding track record of advancing innovative therapies into clinical development, will be invaluable as we continue to expand our pipeline of differentiated antibody therapies. Her strategic insights into next-generation drug development will greatly support our efforts to address unmet medical needs globally.”
Dr. Salter-Cid said: “I am honored to join Harbour BioMed as a scientific advisor. Harbour BioMed has established a unique and strong position in the industry with its world-leading Harbour Mice® technology platform and a growing pipeline. I look forward to working with the team to advance its cutting-edge science and strategic vision, bringing life-changing treatments to patients.”
About Harbour BioMed
Harbour BioMed (stock code: 02142.HK) is a global biopharmaceutical company focused on the research and development of innovative drugs in immunology, oncology, and other therapeutic areas. The company is rapidly expanding its innovative drug pipeline through in-house research, co-development, and diversified international collaborations.
Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both heavy and light chain (H2L2) and heavy-chain-only (HCAb) formats. The immune cell engagers (HBICE®) developed based on the HCAb platform can achieve anti-tumor efficacy unattainable by conventional drug combination therapies. Additionally, the HCAb PLUS™ technology, derived from the HCAb platform, provides comprehensive new molecular solutions for the development of innovative multispecific drugs across various disease areas. Furthermore, leveraging the Harbour Mice® platform, Harbour BioMed has launched its first fully human AI HCAb model—the fully human HCAb generation and screening model—driven by its Hu-mAtrIx™ artificial intelligence (AI) platform, accelerating the development of innovative therapies.
Harbour Mice®, HBICE®, HCAb PLUS™, the single B-cell cloning screening platform, and AI technology together form Harbour BioMed’s next-generation engine for innovative therapeutic antibody discovery. For more information, please visit: www.harbourbiomed.com.